Latest Period
n/a
Security Snapshot
Oncocyte Corporation - Common Shares, No Par Value (OCX) Institutional Ownership
CUSIP: 68235C107
13F Institutional Holders and Ownership History from Q4 2015 to Q2 2025
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Shares, No Par Value
- Symbol
- OCX on Nasdaq
- Shares outstanding
- 28,495,649
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- OCX - Oncocyte Corporation - Common Shares, No Par Value is tracked under CUSIP 68235C107.
- Latest finished 13F holder period is not available.
- 2 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 1 to 0 between Q1 2025 and Q2 2025.
- Reported value moved from $126,921 to $0.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Schedule 13D/G
Open SEC Evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Investment Quick Answers
What is CUSIP 68235C107?
CUSIP 68235C107 identifies OCX - Oncocyte Corporation - Common Shares, No Par Value in SEC 13F datasets.
Where can I see the latest institutional holders?
Use the ownership history tables below to review the newest available institutional filing periods.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 68235C107:
Significant Owners of Oncocyte Corporation - Common Shares, No Par Value (OCX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| BIO-RAD LABORATORIES, INC. | 9.7% | $608,097 | 2,764,078 | BIO-RAD LABORATORIES, INC | 10 Feb 2025 | |||
| SMITH PATRICK W | 10% | $4,221,889 | 1,773,903 | Patrick W. Smith | 26 Dec 2024 |
Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q2 | 0 | $0 | -$126,921 | 0 | |
| 2025 Q1 | 44,378 | $126,921 | -$7,722 | $2.86 | 1 |
| 2024 Q4 | 47,078 | $112,046 | -$29,215 | $2.38 | 1 |
| 2024 Q3 | 59,353 | $169,156 | -$3,224,887 | $2.85 | 1 |
| 2024 Q2 | 1,152,395 | $3,399,565 | +$1,009,560 | $2.95 | 2 |
| 2024 Q1 | 810,171 | $2,373,801 | -$46,191 | $2.93 | 2 |
| 2023 Q4 | 825,936 | $2,049,754 | -$20,365 | $2.49 | 2 |
| 2023 Q3 | 833,802 | $2,716,547 | -$68,395,020 | $3.20 | 2 |
| 2023 Q2 | 91,821,550 | $21,118,229 | +$8,239,978 | $0.23 | 45 |
| 2023 Q1 | 55,657,631 | $19,725,177 | -$1,788,149 | $0.35 | 51 |
| 2022 Q4 | 60,727,357 | $19,486,077 | -$2,603,944 | $0.32 | 55 |
| 2022 Q3 | 66,115,361 | $48,286,884 | -$1,938,715 | $0.73 | 55 |
| 2022 Q2 | 68,689,787 | $61,801,567 | +$12,093,920 | $0.90 | 64 |
| 2022 Q1 | 54,297,692 | $81,004,102 | -$2,234,275 | $1.49 | 76 |
| 2021 Q4 | 55,309,802 | $119,904,059 | -$4,932,956 | $2.17 | 82 |
| 2021 Q3 | 56,556,369 | $201,842,971 | -$4,273,319 | $3.56 | 91 |
| 2021 Q2 | 56,557,145 | $324,629,337 | +$10,097,713 | $5.74 | 88 |
| 2021 Q1 | 54,525,746 | $282,982,492 | +$112,979,747 | $5.19 | 84 |
| 2020 Q4 | 32,820,981 | $78,442,746 | +$4,663,024 | $2.39 | 56 |
| 2020 Q3 | 31,284,691 | $43,477,422 | -$4,537,534 | $1.39 | 55 |
| 2020 Q2 | 32,913,612 | $62,907,536 | +$9,179,739 | $1.91 | 57 |
| 2020 Q1 | 27,664,198 | $67,748,452 | +$4,418,527 | $2.45 | 52 |
| 2019 Q4 | 25,884,634 | $58,219,716 | +$15,568,577 | $2.25 | 50 |
| 2019 Q3 | 18,982,051 | $39,859,066 | +$6,042,313 | $2.10 | 53 |
| 2019 Q2 | 15,958,159 | $39,753,182 | -$2,942,657 | $2.49 | 48 |
| 2019 Q1 | 16,115,175 | $63,651,620 | +$30,829,652 | $3.95 | 45 |
| 2018 Q4 | 8,316,794 | $11,476,217 | -$815,784 | $1.38 | 14 |
| 2018 Q3 | 8,717,557 | $21,792,392 | -$155,396 | $2.50 | 20 |
| 2018 Q2 | 8,778,305 | $22,385,400 | +$392,217 | $2.55 | 24 |
| 2018 Q1 | 8,633,348 | $18,127,749 | +$8,211,749 | $2.10 | 27 |
| 2017 Q4 | 4,675,016 | $21,738,469 | +$1,170,257 | $4.65 | 32 |
| 2017 Q3 | 4,410,134 | $33,296,650 | +$3,970,096 | $7.55 | 28 |
| 2017 Q2 | 3,900,811 | $20,278,960 | +$545,423 | $5.19 | 30 |
| 2017 Q1 | 3,775,245 | $22,466,000 | +$4,356,561 | $5.94 | 25 |
| 2016 Q4 | 3,124,915 | $22,028,000 | +$338,627 | $7.05 | 24 |
| 2016 Q3 | 3,076,924 | $15,505,000 | +$7,596,691 | $5.02 | 20 |
| 2016 Q2 | 1,582,033 | $5,632,178 | -$394,497 | $3.56 | 24 |
| 2016 Q1 | 1,668,822 | $7,688,812 | +$2,644,415 | $4.61 | 35 |
| 2015 Q4 | 1,094,163 | $6,839,000 | +$6,839,000 | $6.24 | 4 |